Royce & Associates LP Buys Shares of 105,526 Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Royce & Associates LP bought a new stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 105,526 shares of the company’s stock, valued at approximately $4,862,000. Royce & Associates LP owned approximately 0.38% of Establishment Labs as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Bamco Inc. NY grew its holdings in Establishment Labs by 13.6% during the 3rd quarter. Bamco Inc. NY now owns 489,386 shares of the company’s stock valued at $21,176,000 after buying an additional 58,611 shares in the last quarter. Mudita Advisors LLP grew its holdings in Establishment Labs by 19.0% during the 3rd quarter. Mudita Advisors LLP now owns 354,801 shares of the company’s stock valued at $15,352,000 after buying an additional 56,700 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in Establishment Labs during the 4th quarter valued at about $12,898,000. Redmile Group LLC grew its holdings in Establishment Labs by 22.9% during the 3rd quarter. Redmile Group LLC now owns 261,803 shares of the company’s stock valued at $11,328,000 after buying an additional 48,779 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Establishment Labs during the 4th quarter valued at about $5,494,000. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Stephens reissued an “overweight” rating and set a $52.00 price objective on shares of Establishment Labs in a report on Thursday, March 6th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Establishment Labs has a consensus rating of “Moderate Buy” and an average target price of $57.40.

Establishment Labs Stock Up 2.7 %

Shares of NASDAQ ESTA opened at $39.83 on Thursday. Establishment Labs Holdings Inc. has a 12 month low of $28.16 and a 12 month high of $60.12. The company has a current ratio of 3.62, a quick ratio of 2.29 and a debt-to-equity ratio of 5.94. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -15.44 and a beta of 0.95. The business has a 50-day moving average of $35.98 and a 200-day moving average of $40.92.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Wednesday, February 26th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.34). The firm had revenue of $44.51 million during the quarter, compared to the consensus estimate of $44.45 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. Sell-side analysts expect that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.